Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 1
2021 4
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
The potential of PARP as a therapeutic target across pediatric solid malignancies.
Keller KM, Koetsier J, Schild L, Amo-Addae V, Eising S, van den Handel K, Ober K, Koopmans B, Essing A, van den Boogaard ML, Langenberg KPS, Jäger N, Kool M, Pfister S, Dolman MEM, Molenaar JJ, van Hooff SR. Keller KM, et al. Among authors: koopmans b. BMC Cancer. 2023 Apr 5;23(1):310. doi: 10.1186/s12885-022-10319-7. BMC Cancer. 2023. PMID: 37020198 Free PMC article.
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.
Cornel AM, Dunnebach E, Hofman DA, Das S, Sengupta S, van den Ham F, Wienke J, Strijker JGM, van den Beemt DAMH, Essing AHW, Koopmans B, Engels SAG, Lo Presti V, Szanto CS, George RE, Molenaar JJ, van Heesch S, Dierselhuis MP, Nierkens S. Cornel AM, et al. Among authors: koopmans b. J Immunother Cancer. 2022 Dec;10(12):e005002. doi: 10.1136/jitc-2022-005002. J Immunother Cancer. 2022. PMID: 36521927 Free PMC article.
Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia.
Schneider P, Crump NT, Arentsen-Peters STCJM, Smith AL, Hagelaar R, Adriaanse FRS, Bos RS, de Jong A, Nierkens S, Koopmans B, Milne TA, Pieters R, Stam RW. Schneider P, et al. Among authors: koopmans b. Exp Hematol Oncol. 2023 Sep 22;12(1):81. doi: 10.1186/s40164-023-00445-8. Exp Hematol Oncol. 2023. PMID: 37740239 Free PMC article.
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma.
Eleveld TF, Vernooij L, Schild L, Koopmans B, Alles LK, Ebus ME, Dandis R, van Tinteren H, Caron HN, Koster J, van Noesel MM, Tytgat GAM, Eising S, Versteeg R, Dolman MEM, Molenaar JJ. Eleveld TF, et al. Among authors: koopmans b. Front Oncol. 2023 Feb 21;13:1130034. doi: 10.3389/fonc.2023.1130034. eCollection 2023. Front Oncol. 2023. PMID: 36895472 Free PMC article.
Two opposing gene expression patterns within ATRX aberrant neuroblastoma.
van Gerven MR, Schild L, van Arkel J, Koopmans B, Broeils LA, Meijs LAM, van Oosterhout R, van Noesel MM, Koster J, van Hooff SR, Molenaar JJ, van den Boogaard ML. van Gerven MR, et al. Among authors: koopmans b. PLoS One. 2023 Aug 4;18(8):e0289084. doi: 10.1371/journal.pone.0289084. eCollection 2023. PLoS One. 2023. PMID: 37540673 Free PMC article.
Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
Wander P, Cheung LC, Pinhanҫos SS, Jones L, Kerstjens M, Arentsen-Peters STCJM, Singh S, Chua GA, Castro PG, Schneider P, Dolman MEM, Koopmans B, Molenaar JJ, Pieters R, Zwaan CM, Kotecha RS, Stam RW. Wander P, et al. Among authors: koopmans b. Leukemia. 2020 Nov;34(11):2898-2902. doi: 10.1038/s41375-020-0895-9. Epub 2020 Jun 2. Leukemia. 2020. PMID: 32488115 No abstract available.
Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.
Keller KM, Eleveld TF, Schild L, van den Handel K, van den Boogaard M, Amo-Addae V, Eising S, Ober K, Koopmans B, Looijenga L, Tytgat GAM, Ylstra B, Molenaar JJ, Dolman MEM, van Hooff SR. Keller KM, et al. Among authors: koopmans b. Front Oncol. 2022 Sep 27;12:929123. doi: 10.3389/fonc.2022.929123. eCollection 2022. Front Oncol. 2022. PMID: 36237330 Free PMC article.
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
Vernooij L, Bate-Eya LT, Alles LK, Lee JY, Koopmans B, Jonus HC, Schubert NA, Schild L, Lelieveld D, Egan DA, Kerstjens M, Stam RW, Koster J, Goldsmith KC, Molenaar JJ, Dolman MEM. Vernooij L, et al. Among authors: koopmans b. Mol Cancer Ther. 2021 Jun;20(6):1161-1172. doi: 10.1158/1535-7163.MCT-20-0666. Epub 2021 Apr 13. Mol Cancer Ther. 2021. PMID: 33850004 Free PMC article.
Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma.
van den Boogaard ML, Oka R, Hakkert A, Schild L, Ebus ME, van Gerven MR, Zwijnenburg DA, Molenaar P, Hoyng LL, Dolman MEM, Essing AHW, Koopmans B, Helleday T, Drost J, van Boxtel R, Versteeg R, Koster J, Molenaar JJ. van den Boogaard ML, et al. Among authors: koopmans b. Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):e2007898118. doi: 10.1073/pnas.2007898118. Proc Natl Acad Sci U S A. 2021. PMID: 34479993 Free PMC article.
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.
Decaesteker B, Denecker G, Van Neste C, Dolman EM, Van Loocke W, Gartlgruber M, Nunes C, De Vloed F, Depuydt P, Verboom K, Rombaut D, Loontiens S, De Wyn J, Kholosy WM, Koopmans B, Essing AHW, Herrmann C, Dreidax D, Durinck K, Deforce D, Van Nieuwerburgh F, Henssen A, Versteeg R, Boeva V, Schleiermacher G, van Nes J, Mestdagh P, Vanhauwaert S, Schulte JH, Westermann F, Molenaar JJ, De Preter K, Speleman F. Decaesteker B, et al. Among authors: koopmans b. Nat Commun. 2018 Nov 19;9(1):4866. doi: 10.1038/s41467-018-06699-9. Nat Commun. 2018. PMID: 30451831 Free PMC article.
13 results